This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thigpen, J. T. Articles by Given, F. T. Search for Related Content PubMed PubMed Citation Articles by Thigpen, J. T. Articles by Given, F. T. Social Bookmarking                            What's this?

Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group

From the Division of Oncology, University of Mississippi School of Medicine, Jackson, MS; Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, and Comprehensive Gynecology, Crouse Irving Memorial Hospital, Syracuse, NY; Department of Gynecologic Oncology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL; Bowman Gray School of Medicine, Carolina Gynecologic Oncology, Winston-Salem, and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC; Division of Gynecologic Oncology, University of California, Irvine Medical Center, Irvine, CA; and Division of Gynecologic Oncology, Eastern Virginia Medical School, Norfolk, VA.

Address reprint requests to Gynecologic Oncology Group Administrative Office, Suite 1945, 1234 Market St, Philadelphia, PA 19107.

PURPOSE: Progestins have definite activity against advanced or recurrent endometrial carcinoma. Both parenteral and oral progestins yield similar serum levels and response rates, which range from 18% to 34%. The one major study that used oral medroxyprogesterone acetate (MPA) noted a response rate at the lower end of the range (18%) and much poorer progression-free and overall survival times (4 and 10.5 months, respectively) than previously reported. The present study sought to confirm this earlier study of oral MPA, to assess the importance of prognostic factors such as histologic grade and receptor levels, and to determine whether a higher dose of MPA would yield a higher response rate.

PATIENTS AND METHODS: Two hundred ninety-nine eligible women with advanced or recurrent endometrial carcinoma were randomized to receive oral MPA either 200 mg/d or 1,000 mg/d until unacceptable toxicity intervened or their disease progressed.

RESULTS: Among 145 patients receiving the low-dose regimen, there were 25 complete (17%) and 11 partial (8%) responses for an overall response rate of 25%. The 154 patients receiving the high-dose regimen experienced 14 (9%) complete and 10 (6%) partial responses for an overall response rate of 15%. Median durations of progression-free survival were 3.2 months and 2.5 months for the low-dose and high-dose regimens, respectively. Median survival durations were 11.1 months and 7.0 months, respectively. The adjusted relative odds of responding to the high-dose regimen compared with the low-dose regimen was 0.61 (90% confidence interval, 0.36 to 1.04). Prognostic factors having a significant impact on the probability of response included initial performance status, age, histologic grade, and progesterone receptor concentration. Compliance with oral therapy was documented with serum levels 1 month after starting therapy, when possible. MPA levels were commensurate with the assigned dose and schedule.

CONCLUSION: Oral MPA is active against endometrial carcinoma. Response to progestin therapy is more frequent among patients with a well-differentiated histology and positive progesterone receptor status. This study provides no evidence to support the use of MPA 1,000 mg/d orally instead of MPA 200 mg/d orally. In fact, the trends suggest the opposite. The use of oral MPA 200 mg/d is a reasonable initial approach to the treatment of advanced or recurrent endometrial carcinoma, particularly those lesions that are well-differentiated and/or progesterone receptor-positive (> 50 fmol/mg cytosol protein). Patients with poorly differentiated and/or progesterone receptor levels less than 50 fmol/mg cytosol protein had only an 8% to 9% response rate.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Wang, P. Hanifi-Moghaddam, E. E. Hanekamp, H. J. Kloosterboer, P. Franken, J. Veldscholte, H. C. van Doorn, P. C. Ewing, J. J. Kim, J. A. Grootegoed, et al. Progesterone Inhibition of Wnt/{beta}-Catenin Signaling in Normal Endometrium and Endometrial Cancer Clin. Cancer Res., September 15, 2009; 15(18): 5784 - 5793. [Abstract] [Full Text] [PDF]

				M.C. Fleisch, Y.C. Chou, R. D. Cardiff, A. Asaithambi, and G. Shyamala Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypia Mol. Hum. Reprod., April 1, 2009; 15(4): 241 - 249. [Abstract] [Full Text] [PDF]

				R. Gogoi, M. Kudla, O. Gil, and D. Fishman The Activity of Medroxyprogesterone Acetate, an Androgenic Ligand, in Ovarian Cancer Cell Invasion Reproductive Sciences, October 1, 2008; 15(8): 846 - 852. [Abstract] [PDF]

				P. A. Foster, L. W. L. Woo, B. V. L. Potter, M. J. Reed, and A. Purohit The Use of Steroid Sulfatase Inhibitors as a Novel Therapeutic Strategy Against Hormone-Dependent Endometrial Cancer Endocrinology, August 1, 2008; 149(8): 4035 - 4042. [Abstract] [Full Text] [PDF]

				E. C. Ward, A. V. Hoekstra, L. J. Blok, P. Hanifi-Moghaddam, J. R. Lurain, D. K. Singh, B. M. Buttin, J. C. Schink, and J. J. Kim The Regulation and Function of the Forkhead Transcription Factor, Forkhead Box O1, Is Dependent on the Progesterone Receptor in Endometrial Carcinoma Endocrinology, April 1, 2008; 149(4): 1942 - 1950. [Abstract] [Full Text] [PDF]

				G. F. Fleming Systemic Chemotherapy for Uterine Carcinoma: Metastatic and Adjuvant J. Clin. Oncol., July 10, 2007; 25(20): 2983 - 2990. [Full Text] [PDF]

				K. Yamazawa, M. Hirai, A. Fujito, H. Nishi, F. Terauchi, H. Ishikura, M. Shozu, and K. Isaka Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer Hum. Reprod., July 1, 2007; 22(7): 1953 - 1958. [Abstract] [Full Text] [PDF]

				M. B. Jones, A. P. Houwink, B. K. Freeman, T. M. Greenwood, J. M. Lafky, W. L. Lingle, A. Berchuck, G. L. Maxwell, K. C. Podratz, and N. J. Maihle The Granulin-Epithelin Precursor Is a Steroid-Regulated Growth Factor in Endometrical Cancer Reproductive Sciences, May 1, 2006; 13(4): 304 - 311. [Abstract] [PDF]

				T. Yahata, K. Fujita, Y. Aoki, and K. Tanaka Long-term conservative therapy for endometrial adenocarcinoma in young women Hum. Reprod., April 1, 2006; 21(4): 1070 - 1075. [Abstract] [Full Text] [PDF]

				H. Ishibashi, T. Suzuki, S. Suzuki, H. Niikawa, L. Lu, Y. Miki, T. Moriya, S.-i. Hayashi, M. Handa, T. Kondo, et al. Progesterone Receptor in Non-Small Cell Lung Cancer--A Potent Prognostic Factor and Possible Target for Endocrine Therapy Cancer Res., July 15, 2005; 65(14): 6450 - 6458. [Abstract] [Full Text] [PDF]

				D. Dai, L. Albitar, T. Nguyen, L. L. Laidler, M. Singh, and K. K. Leslie A therapeutic model for advanced endometrial cancer: Systemic progestin in combination with local adenoviral-mediated progesterone receptor expression Mol. Cancer Ther., January 1, 2005; 4(1): 169 - 175. [Abstract] [Full Text] [PDF]

				S. Aebi Endometrial cancer: a frequent orphan disease Ann. Onc., August 1, 2004; 15(8): 1149 - 1150. [Full Text] [PDF]

				G. F. Fleming, V. L. Filiaci, R. C. Bentley, T. Herzog, J. Sorosky, L. Vaccarello, and H. Gallion Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study Ann. Onc., August 1, 2004; 15(8): 1173 - 1178. [Abstract] [Full Text] [PDF]

				G. F. Fleming, V. L. Brunetto, D. Cella, K. Y. Look, G. C. Reid, A. R. Munkarah, R. Kline, R. A. Burger, A. Goodman, and R. T. Burks Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., June 1, 2004; 22(11): 2159 - 2166. [Abstract] [Full Text] [PDF]

				N. Takai, J. C. Desmond, T. Kumagai, D. Gui, J. W. Said, S. Whittaker, I. Miyakawa, and H. P. Koeffler Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells Clin. Cancer Res., February 1, 2004; 10(3): 1141 - 1149. [Abstract] [Full Text] [PDF]

				F. M. Muggia, J. A. Blessing, J. Sorosky, and G. C. Reid Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., May 1, 2002; 20(9): 2360 - 2364. [Abstract] [Full Text] [PDF]

				T. Thigpen, M. F. Brady, H. D. Homesley, J. T. Soper, and J. Bell Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., January 15, 2001; 19(2): 364 - 367. [Abstract] [Full Text] [PDF]